95 related articles for article (PubMed ID: 16029117)
21. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells.
Van Gompel JJ; Kunnimalaiyaan M; Holen K; Chen H
Mol Cancer Ther; 2005 Jun; 4(6):910-7. PubMed ID: 15956248
[TBL] [Abstract][Full Text] [Related]
22. Tumor suppressor role of notch1 and raf-1 signaling in medullary thyroid cancer cells.
Kunnimalaiyaan M; Haymart MR; Chen H
Transl Oncogenomics; 2007; 2():43-7. PubMed ID: 23641144
[TBL] [Abstract][Full Text] [Related]
23. An achaete-scute homologue essential for neuroendocrine differentiation in the lung.
Borges M; Linnoila RI; van de Velde HJ; Chen H; Nelkin BD; Mabry M; Baylin SB; Ball DW
Nature; 1997 Apr; 386(6627):852-5. PubMed ID: 9126746
[TBL] [Abstract][Full Text] [Related]
24. Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities.
Machens A; Lorenz K; Dralle H
J Intern Med; 2009 Jul; 266(1):114-25. PubMed ID: 19522830
[TBL] [Abstract][Full Text] [Related]
25. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.
Cerrato A; De Falco V; Santoro M
J Mol Endocrinol; 2009 Oct; 43(4):143-55. PubMed ID: 19383830
[TBL] [Abstract][Full Text] [Related]
26. Second nature: biological functions of the Raf-1 "kinase".
Baccarini M
FEBS Lett; 2005 Jun; 579(15):3271-7. PubMed ID: 15943972
[TBL] [Abstract][Full Text] [Related]
27. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.
Drosten M; Stiewe T; Pützer BM
Hum Gene Ther; 2003 Jul; 14(10):971-82. PubMed ID: 12869215
[TBL] [Abstract][Full Text] [Related]
28. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
29. [The treatment of medullary thyroid cancer].
Fujita T; Fujimori M
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1627-31. PubMed ID: 19838021
[TBL] [Abstract][Full Text] [Related]
30. Achaete-scute homolog 1 expression closely correlates with endocrine phenotype and degree of differentiation in sinonasal neuroendocrine tumors.
Taggart MW; Hanna EY; Gidley P; Weber RS; Bell D
Ann Diagn Pathol; 2015 Jun; 19(3):154-6. PubMed ID: 25892663
[TBL] [Abstract][Full Text] [Related]
31. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571.
Skinner MA; Safford SD; Freemerman AJ
Anticancer Res; 2003; 23(5A):3601-6. PubMed ID: 14666655
[TBL] [Abstract][Full Text] [Related]
32. Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase.
Quidville V; Segond N; Pidoux E; Cohen R; Jullienne A; Lausson S
Endocrinology; 2004 May; 145(5):2561-71. PubMed ID: 14736730
[TBL] [Abstract][Full Text] [Related]
33. Medullary thyroid carcinoma: surgical treatment advances.
Dionigi G; Bianchi V; Rovera F; Boni L; Piantanida E; Tanda ML; Dionigi R; Bartalena L
Expert Rev Anticancer Ther; 2007 Jun; 7(6):877-85. PubMed ID: 17555398
[TBL] [Abstract][Full Text] [Related]
34. Low telomerase activity: possible role in the progression of human medullary thyroid carcinoma.
Stadler G; Wieser M; Streubel B; Stift A; Friedl J; Gnant M; Niederle B; Beham A; Katinger H; Pfragner R; Grillari J; Voglauer R
Eur J Cancer; 2008 Apr; 44(6):866-75. PubMed ID: 18296042
[TBL] [Abstract][Full Text] [Related]
35. ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells.
Kappes A; Vaccaro A; Kunnimalaiyaan M; Chen H
J Surg Res; 2006 Jun; 133(1):42-5. PubMed ID: 16603190
[TBL] [Abstract][Full Text] [Related]
36. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L; Ye L; Gagel RF
J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
[TBL] [Abstract][Full Text] [Related]
37. Management of medullary thyroid carcinoma.
Jiménez C; Hu MI; Gagel RF
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
[TBL] [Abstract][Full Text] [Related]
38. Differential display in primary and metastatic medullary thyroid carcinoma.
Musholt TJ; Goodfellow PJ; Scheumann GF; Pichlmayr R; Wells SA; Moley JF
J Surg Res; 1997 Apr; 69(1):94-100. PubMed ID: 9202653
[TBL] [Abstract][Full Text] [Related]
39. Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer.
Cook M; Yu XM; Chen H
Am J Transl Res; 2010 Feb; 2(1):119-25. PubMed ID: 20182588
[TBL] [Abstract][Full Text] [Related]
40. Transforming growth factor-beta 1 induces growth inhibition of a human medullary thyroid carcinoma cell line despite an increase in steady state c-myc messenger ribonucleic acid levels.
Khosla S; Oursler MJ; Schroeder MJ; Eberhardt NL
Endocrinology; 1994 Nov; 135(5):1887-93. PubMed ID: 7956909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
